Analysts Set Gilead Sciences, Inc. (NASDAQ:GILD) PT at $159.04

Gilead Sciences, Inc. (NASDAQ:GILD) has received an average rating of “Moderate Buy” from the twenty-nine brokerages that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and twenty-six have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $159.0370.

Several research analysts have recently weighed in on GILD shares. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research note on Monday, July 6th. Rothschild & Co Redburn reduced their price objective on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Leerink Partners decreased their target price on Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Finally, Morgan Stanley dropped their price target on shares of Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, July 8th.

Gilead Sciences Trading Down 1.5%

Gilead Sciences stock opened at $134.28 on Monday. Gilead Sciences has a 12 month low of $107.75 and a 12 month high of $157.29. The company has a market capitalization of $166.72 billion, a price-to-earnings ratio of 18.29 and a beta of 0.32. The business’s fifty day simple moving average is $129.73 and its two-hundred day simple moving average is $135.22. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period last year, the company earned $1.81 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts predict that Gilead Sciences will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the completion of the sale, the chief executive officer directly owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. This represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares in the company, valued at $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 77,000 shares of company stock worth $9,978,740 in the last ninety days. Insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

A number of institutional investors have recently bought and sold shares of GILD. Brighton Jones LLC raised its holdings in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 2,450 shares during the period. Bison Wealth LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at $215,000. Sivia Capital Partners LLC lifted its holdings in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after acquiring an additional 602 shares during the last quarter. Ieq Capital LLC lifted its holdings in shares of Gilead Sciences by 12.0% in the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after acquiring an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC boosted its stake in shares of Gilead Sciences by 18.6% during the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after purchasing an additional 674 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.